Payment overview · 2025
General Payments
$1,037.09
50 reported records · 21 companies
Healthcare provider profile · identity verified
Sandra B Marcotte, DO
Allopathic & Osteopathic Physicians|Family Medicine · DYER, IN · NPI 1619945797
Verified facts
What the public records show
CMS Open Payments records show Sandra B Marcotte, DO received $1,037.09 in general payments during 2025 across 50 reported records.
Novo Nordisk Inc accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Mounjaro, Ozempic, Shingrix, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $263.44 | 25.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $112.28 | 10.8% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $91.86 | 8.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.73 | 7.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.89 | 4.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.28 | 4.8% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $49.49 | 4.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $41.61 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.37 | 3.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.85 | 3.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.76 | 2.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $29.36 | 2.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.26 | 2.3% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.00 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.61 | 2.2% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $19.80 | 1.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $19.46 | 1.9% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $18.40 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.86 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.50 | 1.5% | 1 | 2025 |
| VivaQuant Inc, dba Rhythm Express | Unresolved — no canonical attribution shown | $14.28 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,037.09 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $151.38 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $91.86 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.89 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.28 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $49.49 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.29 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.49 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $41.61 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.37 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.85 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.24 | 2 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $29.76 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $29.36 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.36 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| RHYTHM EXPRESS Normalized: rhythm express |
Device | VivaQuant Inc, dba Rhythm Express | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 36 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 75 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 34 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
34 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 659 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 417 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 79 |
| Omeprazole | Omeprazole | 267 | 69 |
| Meloxicam | Meloxicam | 247 | 81 |
| Alprazolam | Alprazolam | 231 | 60 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 221 | 65 |
| Metformin Hcl | Metformin Hcl | 208 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 67 |
| Losartan Potassium | Losartan Potassium | 194 | 55 |
| Simvastatin | Simvastatin | 193 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 175 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 46 |
| Lisinopril | Lisinopril | 149 | 47 |
| Furosemide | Furosemide | 144 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 39 |
| Montelukast Sodium | Montelukast Sodium | 121 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 55 |
| Ozempic | Semaglutide | 102 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 26 |
| Gabapentin | Gabapentin | 96 | 32 |
| Sertraline Hcl | Sertraline Hcl | 94 | 26 |
| Carvedilol | Carvedilol | 91 | 24 |
| Trazodone Hcl | Trazodone Hcl | 91 | 27 |
| Allopurinol | Allopurinol | 90 | 24 |
| Tramadol Hcl | Tramadol Hcl | 87 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 25 |
| Eliquis | Apixaban | 75 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 21 |
| Potassium Chloride | Potassium Chloride | 64 | 16 |
| Famotidine | Famotidine | 61 | 25 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 16 |
| Celecoxib | Celecoxib | 55 | 21 |
| Ezetimibe | Ezetimibe | 55 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 25 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Glipizide Er | Glipizide | 40 | 14 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 11 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 14 |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Clonazepam | Clonazepam | 34 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 28 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 11 |
| Fluconazole | Fluconazole | 25 | 13 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 17 |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 13 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Wegovy | Semaglutide | 19 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,037.09 · 50 records | Novo Nordisk Inc | AIRSUPRA, APTIMA, AREXVY, Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ETERNA, FARXIGA, GEMTESA, INSPIRE, ImmunoCAP, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, Ocrevus Zunovo, Ozempic, PYRUKYND, QULIPTA, REPATHA, REXULTI, RHYTHM EXPRESS, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error